Médecine

Paramédical

Autres domaines


S'abonner

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics - 14/03/19

Doi : 10.1016/j.jaad.2018.11.057 
Alan Menter, MD a : (Co-Chair), Bruce E. Strober, MD, PhD b, c, Daniel H. Kaplan, MD, PhD d, Dario Kivelevitch, MD a, Elizabeth Farley Prater, MD e, Benjamin Stoff, MD, MA f, April W. Armstrong, MD, MPH g, Cody Connor, MD h, Kelly M. Cordoro, MD i, Dawn M.R. Davis, MD j, Boni E. Elewski, MD h, Joel M. Gelfand, MD, MSCE k, Kenneth B. Gordon, MD l, Alice B. Gottlieb, MD, PhD m, Arthur Kavanaugh, MD n, Matthew Kiselica o, Neil J. Korman, MD, PhD p, Daniela Kroshinsky, MD, MPH q, Mark Lebwohl, MD m, Craig L. Leonardi, MD r, Jason Lichten, MD o, Henry W. Lim, MD s, Nehal N. Mehta, MD, MSCE t, Amy S. Paller, MD u, Sylvia L. Parra, MD v, Arun L. Pathy, MD w, Reena N. Rupani, MD r, Michael Siegel, PhD o, Emily B. Wong, MD x, Jashin J. Wu, MD y, Vidhya Hariharan, PhD z, , Craig A. Elmets, MD h : (Co-Chair)
a Baylor Scott and White, Dallas, Texas 
b University of Connecticut, Farmington, Connecticut 
c Probity Medical Research, Waterloo, Ontario, Canada 
d University of Pittsburgh, Pittsburgh, Pennsylvania 
e University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 
f Emory University School of Medicine, Atlanta, Georgia 
g University of Southern California, Los Angeles, San Francisco 
h University of Alabama, Birmingham, Alabama 
i University of California, San Francisco School of Medicine, Department of Dermatology, San Francisco, California 
j Mayo Clinic, Rochester, Minnesota 
k University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
l Medical College of Wisconsin, Milwaukee, Wisconsin 
m Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York 
n University of California San Diego, San Diego, California 
o National Psoriasis Foundation, Portland, Oregon 
p University Hospitals Cleveland Medical Center, Cleveland, Ohio 
q Massachusetts General Hospital, Boston, Massachusetts 
r Central Dermatology, St. Louis, Missouri 
s Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
t National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 
u Northwestern University Feinberg School of Medicine, Chicago, Illinois 
v Dermatology and Skin Surgery, Sumter, South Carolina 
w Colorado Permanente Medical Group, Centennial, Colorado 
x San Antonio Uniformed Services Health Education Consortium, Joint-Base San Antonio 
y Dermatology Research and Education Foundation, Irvine, California 
z American Academy of Dermatology, Rosemont, Illinois 

Corresponding author: Vidhya Hariharan, PhD, American Academy of Dermatology, 9500 West Bryn Mawr Ave, Rosemont, IL 60018.American Academy of Dermatology9500 West Bryn Mawr AveRosemontIL60018

Abstract

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.

Le texte complet de cet article est disponible en PDF.

Key words : biologic agents, clinical guidelines for psoriasis, dermatology, guidelines, monoclonal antibodies, psoriasis, skin disease

Abbreviations used : AAD, BSA, FDA, HAART, IBD, IL, m-PPPASI, NAPSI, NB-UVB, NPF, PASI, PASI 75, PASI 90, PASI 100, PPPASI, PsA, PSSI, QOL, RCT, SCC, WG


Plan


 Funding sources: None.
 American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The American Academy of Dermatology conflict of interest policy summary may be viewed at www.aad.org. The conflicts of interest of the individual working group members are listed in the text of this guideline.
 Reprints not available from the authors.


© 2018  American Academy of Dermatology, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 4

P. 1029-1072 - avril 2019 Retour au numéro
Article précédent Article précédent
  • Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study
  • Lieke C.J. van Delft, Patty J. Nelemans, Maud H.E. Jansen, Aimee H.M.M. Arits, Marieke H. Roozeboom, Myrurgia A. Hamid, Klara Mosterd, Nicole W.J. Kelleners-Smeets
| Article suivant Article suivant
  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
  • Craig A. Elmets, Craig L. Leonardi, Dawn M.R. Davis, Joel M. Gelfand, Jason Lichten, Nehal N. Mehta, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Boni E. Elewski, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Dario Kivelevitch, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Henry W. Lim, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth Farley Prater, Reena Rupani, Michael Siegel, Benjamin Stoff, Bruce E. Strober, Emily B. Wong, Jashin J. Wu, Vidhya Hariharan, Alan Menter

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.